Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Retivance is a topical skin rejuvenation formulation developed by Obagi Medical Products, primarily utilized for its anti-aging and skin-smoothing properties. The formulation's core active ingredient is retinaldehyde (0.1%), a stable precursor to retinoic acid that promotes cellular turnover and collagen production with a lower irritation profile compared to traditional tretinoin. It also incorporates Palmitoyl Tripeptide-5, a synthetic peptide designed to mimic the body's natural mechanism for activating Transforming Growth Factor-beta (TGF-beta), thereby stimulating collagen synthesis. Complementary ingredients such as Chamomilla recutita flower extract provide anti-inflammatory benefits to soothe the skin and reduce visible redness. Retivance is marketed to improve the appearance of fine lines, wrinkles, and skin texture while being suitable for sensitive skin types.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Retivance.